MX369556B - Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac). - Google Patents

Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).

Info

Publication number
MX369556B
MX369556B MX2017015662A MX2017015662A MX369556B MX 369556 B MX369556 B MX 369556B MX 2017015662 A MX2017015662 A MX 2017015662A MX 2017015662 A MX2017015662 A MX 2017015662A MX 369556 B MX369556 B MX 369556B
Authority
MX
Mexico
Prior art keywords
preparation
processes
galnac
acid derivatives
galnac acid
Prior art date
Application number
MX2017015662A
Other languages
English (en)
Spanish (es)
Other versions
MX2017015662A (es
Inventor
Trussardi René
Lill Joerg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017015662A publication Critical patent/MX2017015662A/es
Publication of MX369556B publication Critical patent/MX369556B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08Polyoxyalkylene derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/20Diazonium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/10Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond
    • C07C67/11Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond being mineral ester groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18Fluorenes; Hydrogenated fluorenes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017015662A 2015-08-06 2016-08-02 Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac). MX369556B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15180058 2015-08-06
PCT/EP2016/068361 WO2017021385A1 (en) 2015-08-06 2016-08-02 Processes for the preparation of galnac acid derivatives

Publications (2)

Publication Number Publication Date
MX2017015662A MX2017015662A (es) 2018-04-18
MX369556B true MX369556B (es) 2019-11-12

Family

ID=54056068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015662A MX369556B (es) 2015-08-06 2016-08-02 Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).

Country Status (14)

Country Link
US (1) US10597417B2 (OSRAM)
EP (1) EP3331892B1 (OSRAM)
JP (1) JP6940477B2 (OSRAM)
KR (1) KR102579520B1 (OSRAM)
CN (1) CN107709342B (OSRAM)
AU (1) AU2016302697B2 (OSRAM)
CA (1) CA2982825C (OSRAM)
ES (1) ES2744437T3 (OSRAM)
HR (1) HRP20191589T1 (OSRAM)
IL (1) IL256528B (OSRAM)
MX (1) MX369556B (OSRAM)
PL (1) PL3331892T3 (OSRAM)
SI (1) SI3331892T1 (OSRAM)
WO (1) WO2017021385A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018215049A1 (en) 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Process for galnac oligonucleotide conjugates
KR20200116088A (ko) 2018-01-26 2020-10-08 에프. 호프만-라 로슈 아게 방사성 표지된 올리고뉴클레오티드 및 이의 제조 방법
CN111699007A (zh) * 2018-01-29 2020-09-22 豪夫迈·罗氏有限公司 用于制备GalNAc寡核苷酸缀合物的方法
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
AR118949A1 (es) * 2019-05-20 2021-11-10 Hoffmann La Roche Proceso para preparar epímeros de fosforamidita de galnac
CN114008061B (zh) 2019-06-20 2024-03-12 豪夫迈·罗氏有限公司 放射性标记的moem型寡核苷酸及其制备方法
CN110734372B (zh) * 2019-09-30 2024-09-24 兰州交通大学 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸(apea-9)的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US156917A (en) * 1874-11-17 Improvement in car-couplings
US133170A (en) * 1872-11-19 Improvement in wheelbarrows
US1185198A (en) * 1912-11-25 1916-05-30 Elliott Co Tube-cleaning apparatus.
JP5004234B2 (ja) * 2006-11-10 2012-08-22 独立行政法人産業技術総合研究所 膜マイクロドメイン又はコレステロール認識タンパク質検出用高感度分子プローブ
AU2009327322A1 (en) * 2008-12-19 2011-06-30 Pinnacle Pharmaceuticals, Inc. Phenazopyridine compounds
CA2755965C (en) * 2009-03-19 2019-04-16 The Johns Hopkins University Psma-targeting compounds and uses thereof
WO2011053614A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Crystalline cdm-nag and methods for producing same
RS54578B1 (sr) * 2010-02-24 2016-06-30 Arrowhead Research Corporation Preparati za ciljano dopremanje sirnk
LT2603513T (lt) * 2010-08-10 2020-05-25 Takeda Pharmaceutical Company Limited Heterociklinis junginys ir jo panaudojimas kaip ampa receptoriaus teigiamo alosterinio moduliatoriaus
JP2014504295A (ja) * 2010-12-17 2014-02-20 アローヘッド リサーチ コーポレイション siRNA用ガラクトースクラスター−薬物動態調節剤標的指向部分
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
BR112015027322A8 (pt) 2013-05-01 2018-01-02 Isis Pharmaceuticals Inc Compostos antissenso conjugados e sua utilização
MX391977B (es) 2013-06-27 2025-03-21 Roche Innovation Ct Copenhagen As Oligómeros antisentido y conjugados con diana en la proteína-convertasa subtilisina/kexina tipo 9(pcsk9).
KR20160083876A (ko) * 2013-11-14 2016-07-12 로슈 이노베이션 센터 코펜하겐 에이/에스 ApoB 안티센스 접합체 화합물
EP3845547A1 (en) 2014-05-01 2021-07-07 Ionis Pharmaceuticals, Inc. Galnac3 conjugated modified oligonucleotide for modulating angiopoietin-like 3 expression

Also Published As

Publication number Publication date
PL3331892T3 (pl) 2019-11-29
JP2018523643A (ja) 2018-08-23
US20180162894A1 (en) 2018-06-14
HK1250717A1 (zh) 2019-01-11
HRP20191589T1 (hr) 2019-12-13
SI3331892T1 (sl) 2019-10-30
KR102579520B1 (ko) 2023-09-15
EP3331892A1 (en) 2018-06-13
MX2017015662A (es) 2018-04-18
EP3331892B1 (en) 2019-07-03
WO2017021385A1 (en) 2017-02-09
ES2744437T3 (es) 2020-02-25
CN107709342A (zh) 2018-02-16
AU2016302697A1 (en) 2017-10-26
KR20180030783A (ko) 2018-03-26
US10597417B2 (en) 2020-03-24
JP6940477B2 (ja) 2021-09-29
CA2982825C (en) 2023-10-17
AU2016302697B2 (en) 2020-10-29
BR112017021926A2 (pt) 2018-07-03
CA2982825A1 (en) 2017-02-09
IL256528B (en) 2020-01-30
IL256528A (en) 2018-02-28
CN107709342B (zh) 2021-09-03

Similar Documents

Publication Publication Date Title
MX2017015662A (es) Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
CL2019003154A1 (es) Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079)
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MX378999B (es) Fosforamidita de agrupacion de n-acetilgalactosamina (galnac).
SG10201809518QA (en) Processes of preparing a jak1 inhibitor and new forms thereto
EP3459925A4 (en) METHOD FOR PRODUCING 2-HYDROXYL-4- (2,3-DISUBSTITUTED BENZYLOXY) -5-SUBSTITUTED BENZALDEHYDE DERIVATIVE
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
JO3706B1 (ar) مشتقات H4- بيرولو[2,3-c] بيريدين-4- ون
GEP20207160B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CY1122138T1 (el) Νεα ενωση και διαδικασια
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
JO3722B1 (ar) مثبطات 6-(5- هيدروكسي-1h- بيرازول-1- يل) و مشتقات نيكوتيناميد واستخدامها كمثبطات
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
NZ746906A (en) Oxaborole esters and uses thereof
MX377644B (es) 6.7.beta-epóxidos esteroideos como intermedios químicos.
MX2020007915A (es) Proceso para la preparacion de conjugados de oligonucleotidos de n-acetilgalactosamina (galnac).
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
MY185367A (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
PH12014501712A1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
MX2018011877A (es) Proceso mejorado para la preparacion de tartrato de butorfanol.
EP3447042A4 (en) PRODUCTION PROCESS OF 1,2-DICHLOROHEXAFLUORCYCLOPENTEN
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
EP3995475A4 (en) PROCESS FOR PURIFICATION OF 1,3-BUTADIENE
EA201891866A1 (ru) N,N-ДИМЕТИЛ-3-[[5-(3-МЕТИЛ-2-ОКСО-1-ТЕТРАГИДРОПИРАН-4-ИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-8-ИЛ)-2-ПИРИДИЛ]ОКСИ]ПРОПАН-1-АМИНОКСИД В КАЧЕСТВЕ МОДУЛЯТОРА АТМ-КИНАЗЫ (МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ) ДЛЯ ЛЕЧЕНИЯ РАКА

Legal Events

Date Code Title Description
FG Grant or registration